Skip to content

Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis

Phase III, National, Multicenter, Randomized, Single-blind, Non-inferiority to Compare the Efficacy of Mometasone Nasal Gel Compared to Mometasone Nasal Spray in the Treatment of Persistent or Intermittent Allergic Rhinitis in Childrens

Status
Withdrawn
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02953366
Enrollment
0
Registered
2016-11-02
Start date
2019-05-31
Completion date
2020-05-31
Last updated
2020-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Brief summary

The purpose of this study is to evaluate the non-inferiority of the clinical efficacy of the mometasone nasal gel in the treatment of allergic rhinitis.

Interventions

The patient should administer 1 spray in each nostril once daily.

The patient should administer 1 spray in each nostril once daily.

Sponsors

EMS
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
6 Years to 11 Years
Healthy volunteers
No

Inclusion criteria

* Signed Consent of the patient; * Clinical diagnosis of moderate - severe persistent allergic rhinitis according to ARIA classification(Allergic Rhinitis and Its Impact on Asthma);

Exclusion criteria

* Patients with any clinically significant disease that in the investigator is opinion can´t participate in the study; * Patients with any laboratory finding or image finding that in the investigator is opinion can´t participate in the clinical trial; * Patients with history of hypersensitivity to any of the formula compounds; * Participation in clinical trial in the year prior to this study; * Pregnancy or risk of pregnancy and lactating patients; * Patients who were in use of drugs that can interfere with evaluation; * Decongestants dependent patients or patients receiving allergen specific immunotherapy; * Patients on treatment with monoamine oxidase inhibitors (MAOIs).

Design outcomes

Primary

MeasureTime frame
Efficacy of allergic rhinitis treatment based proportion of participants who show at least moderate relief.28 days

Secondary

MeasureTime frame
Safety will be evaluated by the adverse events occurrences28 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026